Small Molecule, Monoclonal Antibody, Adjuvant, Reformulation

Curative Biotechnology focuses on developing innovative therapeutic drug candidates aimed at addressing unmet medical needs, particularly in the realm of rare diseases. The company has established a pipeline that includes programs in three primary therapeutic areas: degenerative eye disease, neuro-oncology, and infectious diseases. One of their key assets, IMT504, is an oligodeoxynucleotide (ODN) that stimulates immune responses and has shown promise in treating rabies, a disease with a nearly 100% fatality rate once symptoms appear. Additionally, Curative is reformulating metformin, a widely used diabetes medication, to target various forms of retinal degeneration, including age-related macular degeneration (AMD), by leveraging its ability to activate specific cellular pathways.

In the oncology space, Curative is advancing CUBT906, a monoclonal antibody drug conjugate designed to target CD56-positive brain tumors, such as glioblastoma. This innovative approach utilizes a highly potent cytotoxic drug linked to a monoclonal antibody, allowing for targeted delivery directly to tumor sites while minimizing systemic exposure. The company’s commitment to addressing rare and orphan diseases through these advanced therapeutic strategies underscores its mission to provide effective treatments where few options currently exist.

United States

We Focus on Identifying, Acquiring and Developing Disease-Modifying Therapeutic Drug Candidates with Rare Disease Indications

Curative Biotechnology

Company Details